Rose Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cruelty Free International Seeks ‘More Humane’ REACH With Phase-In Registrations Now Wrapped

Executive Summary

The NGO unveiled a six-point plan in July to reduce animal suffering under the European chemical regulation. Needs include greater funding to advance alternative methods and less red tape to encumber their regulatory approval, according to the animal-welfare group.

Advertisement

Related Content

Stakeholders Converge On California For Animal-Testing Bill Showdown
REACH Phase-In Registration Is Over. Now What?
European Parliament Members To Push For Global Cosmetic Animal Test Ban
ECHA: Non-Animal Tests For Complex Toxicity Endpoints Not 'Foreseeable'
Industry, NGOs Still Divided On Alternative Testing With EU Ingredient Innovation Stalled
Animal-Tested Cosmetic Ingredients In The EU: One Big Question Remains
ECHA Shirking Animal-Test Avoidance Duties? Challenge May Go To EU Court
REACH Registrants Should Bone Up On Alternative Test Requirements – ECHA

Topics

Advertisement
UsernamePublicRestriction

Register

RS121756

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel